GHENT, BELGIUM--(Marketwired - August 27, 2013) - Ablynx (EURONEXT BRUSSELS: ABLX) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Gimv NV, Adviesbeheer Gimv Life Sciences 2004 NV and Biotech Fonds Vlaanderen NV.
The above shareholders notified that they have dropped below the 10% threshold and now hold 4,831,860 Ablynx shares.
Gimv NV controls Adviesbeheer Gimv Life Sciences NV and Adviesbeheer Gimv Life Sciences 2004 NV. Gimv NV (2,033,399 voting rights), Adviesbeheer Gimv Life Sciences NV (0 voting rights), Adviesbeheer Gimv Life Sciences 2004 NV (360,973 voting rights) and Biotech Fonds Vlaanderen NV (2,437,488 voting rights) are acting in mutual agreement. The Flemish Region in Belgium is the ultimate shareholder of Biotech Fonds Vlaanderen NV.
Full versions of all transparency notifications are available on the website of Ablynx, under the section Investors.
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and six Nanobodies at clinical development stage. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck Serono, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
Press release in pdf format: http://hugin.info/137912/R/1725077/575151.pdf